NeoGenomics is trading 10.22% up now at $19.14 after CMS expanded Medicare coverage for its RaDaR ST molecular residual disease assay on August 26, 2026.
- Coverage includes monitoring responses to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.
- This creates a third Medicare-covered indication and could broaden test utilization.
- Shares show strong live-session momentum versus the August 26 close of $17.37.